Physician profile
Toby A Davis
NPI 1891987467
$1,343.84
in general payments reported to CMS, 2019-2025
18 companies · $60.74 in 2025
The $60.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2022: $28.56 · 2024: $1,047 · 2025: $60.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $274.37 | 2019-2024 | |
| Amgen INC. | $265.09 | 2024-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $168.73 | 2024 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $123.93 | 2024-2025 | |
| Abbvie INC. | $88.65 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $59.77 | 2024 | Rexulti |
| Dexcom, INC. | $44.88 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $40.03 | 2024 | Trelegy Ellipta |
| Antares Pharma, INC. | $39.87 | 2024 | Xyosted |
| Exact Sciences Corporation | $36.86 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $35.82 | 2024 | Spravato |
| Novo Nordisk INC | $35.10 | 2024 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.45 | 2024 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $32.30 | 2024 | Yupelri |
| Astellas Pharma US INC | $25.81 | 2024 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $13.78 | 2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $13.33 | 2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $12.07 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.